ALT / Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, unde more_horizontal

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n more_horizontal

Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March more_horizontal

Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greate more_horizontal

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line more_horizontal

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that m more_horizontal

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that i more_horizontal

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% more_horizontal